Clinical trialPhase 2Active not recruiting

mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma

Randomized Phase 2 Study of mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT04986930 ↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome: Ongoing
Phase: Phase 2
Status: Active not recruiting
Study type: Interventional
Start: 14 August 2021
Expected end: 14 December 2025
Enrollment: 92 participants
Sites: 1
Primary outcomes: 1-year progression-free survival rate
Sponsor: Other
Results posted: No
Last update: 28 January 2025

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Ask this document

Papers 5